王一诺, 代晓寒, 严花, 单祎文, 赵霞. 固本防哮饮调控铁代谢抑制气道上皮细胞铁死亡改善哮喘缓解期的机制研究J. 药学学报, 2026, 61(1): 204-213. DOI: 10.16438/j.0513-4870.2025-0795
引用本文: 王一诺, 代晓寒, 严花, 单祎文, 赵霞. 固本防哮饮调控铁代谢抑制气道上皮细胞铁死亡改善哮喘缓解期的机制研究J. 药学学报, 2026, 61(1): 204-213. DOI: 10.16438/j.0513-4870.2025-0795
WANG Yi-nuo, DAI Xiao-han, YAN Hua, SHAN Yi-wen, ZHAO Xia. Effect of Guben Fangxiao Decoction regulating iron metabolism, inhibiting airway epithelial cells ferroptosis and improving the remission period of asthmaJ. Acta Pharmaceutica Sinica, 2026, 61(1): 204-213. DOI: 10.16438/j.0513-4870.2025-0795
Citation: WANG Yi-nuo, DAI Xiao-han, YAN Hua, SHAN Yi-wen, ZHAO Xia. Effect of Guben Fangxiao Decoction regulating iron metabolism, inhibiting airway epithelial cells ferroptosis and improving the remission period of asthmaJ. Acta Pharmaceutica Sinica, 2026, 61(1): 204-213. DOI: 10.16438/j.0513-4870.2025-0795

固本防哮饮调控铁代谢抑制气道上皮细胞铁死亡改善哮喘缓解期的机制研究

Effect of Guben Fangxiao Decoction regulating iron metabolism, inhibiting airway epithelial cells ferroptosis and improving the remission period of asthma

  • 摘要: 本研究旨在探讨固本防哮饮(Guben Fangxiao Decoction, GBFXD) 能否通过调控铁代谢抑制气道上皮细胞铁死亡, 发挥防治哮喘缓解期的作用。动物实验已获得南京中医药大学动物实验中心伦理委员会批准(批准号: 202401A044)。雌性Balb/c小鼠随机分为对照组、模型组、GBFXD-L、M、H 12、24、36 g·kg-1 (生药)、孟鲁司特钠组(montelukast sodium, Mont, 2.6 mg·kg-1)。除对照组外, 其他各组小鼠采用卵白蛋白(ovalbumins, OVA) 建立哮喘缓解期小鼠模型。观察小鼠肺组织炎性损伤情况; 检测肺组织中白细胞介素33 (interleukin 33, IL-33)、肿瘤坏死因子α (tumor necrosis factor-α, TNF-α)、高迁移率组蛋白B1 (high mobility histone B1, HMGB1) 水平, 并测定脂质过氧化物(lipid peroxides, LPO)、亚铁离子(ferrous ions, Fe2+) 含量; 观察肺组织溶质载体家族7成员11 (solute carrier family 7 member 11, SLC7A11)、谷胱甘肽过氧化物酶4 (glutathione peroxidase 4, GPX4)、长链酰基辅酶A合酶4 (long-chain acyl-CoA synthase 4, ACSL4) 的表达情况; 检测人气道上皮细胞(human bronchial epithelial cells, 16HBE) 中SLC7A11、GPX4、ACSL4及转铁蛋白受体1 (transferrin receptor 1, TFR1)、铁蛋白重链1 (ferritin heavy chain 1, FTH1)、核受体共激活因子4 (nuclear receptor co-activator 4, NCOA4)、膜铁转运蛋白1 (ferroportin 1, FPN1) 的蛋白及Fe2+表达水平。苏木精-伊红染色(hematoxylin-eosin staining, HE) 结果显示, GBFXD可减少小鼠气道周围炎症浸润(P < 0.05)。酶联免疫法(enzyme-linked immunosorbent assay, ELISA) 结果显示, GBFXD下调小鼠肺组织IL-33、TNF-α、HMGB1水平(P < 0.05)。免疫组化结果显示, GBFXD能上调小鼠肺组织SLC7A11、GPX4的表达, 下调ACSL4的表达(P < 0.05)。生化结果显示, GBFXD可减少小鼠肺组织LPO积累, 减少小鼠肺组织及16HBE细胞Fe2+积累(P < 0.05)。Western blot结果显示, GBFXD可回调铁死亡诱导剂干预下16HBE细胞SLC7A11、GPX4、FTH1、FPN1的低表达, ACSL4、TFR1、NCOA4的高表达(P < 0.05)。上述研究结果表明, 固本防哮饮能够抑制气道上皮细胞铁死亡, 减少气道上皮损伤, 减轻气道炎症, 防治哮喘缓解期, 其抑制铁死亡的作用机制可能与影响铁代谢相关蛋白表达, 减少Fe2+积累有关。

     

    Abstract: This study aims to observe the effects of Guben Fangxiao Decoction (GBFXD) on inhibit ferroptosis of airway epithelial cells by regulating iron metabolism, thereby playing a role in the prevention and treatment of the asthma remission. The animal experiments have been approved by the Ethics Committee of the Animal Experiment Center of Nanjing University of Chinese Medicine (approval number: 202401A044). Female Balb/c mice were randomly divided into control group, model group, GBFXD low-, medium-, and high-dose groups 12, 24, 36 g·kg-1 (crude drug), and montelukast sodium group (2.6 mg·kg-1). Except for the control group, the other groups of mice were used to establish a mouse model of the remission period of asthma with ovalbumin. Hematoxylin-eosin staining (HE) of the lung tissue of mice was observed and the inflammation score was conducted; the levels of interleukin 33 (IL-33), tumor necrosis factor-α (TNF-α), and high mobility histone B1 (HMGB1) in the lung tissue were detected by enzyme-linked immunosorbent assay (ELISA); the expression of solute carrier family 7 member 11 (SLC7A11), glutathione peroxidase 4 (GPX4), and long-chain acyl-CoA synthase 4 (ACSL4) in the lung tissue was observed by immunohistochemistry; the content of lipid peroxides (LPO) and ferrous ions (Fe2+) in the lung tissue was detected. The protein expression levels of SLC7A11, GPX4, ACSL4, transferrin receptor 1 (TFR1), ferritin heavy chain 1 (FTH1), nuclear receptor co-activator 4 (NCOA4), and ferroportin 1 (FPN1) in 16HBE of each group were detected by Western blot; the expression of Fe2+ in 16HBE of each group was detected. The results of HE staining of lung tissue showed that GBFXD could reduce inflammatory infiltration in the periairway region of mice (P < 0.05). The results of ELISA showed that GBFXD down-regulated the levels of IL-33, TNF-α and HMGB1 in lung tissue of mice (P < 0.05). Immunohistochemical results showed that GBFXD could up-regulate the expression of SLC7A11 and GPX4 in the lung tissue of mice, and down-regulate the expression of ACSL4 (P < 0.05). Biochemical results showed that GBFXD treatment reduced LPO accumulation in lung tissue of mice and Fe2+ accumulation in lung tissue and 16HBE cells (P < 0.05). Western blot results showed that GBFXD up-regulated the expressions of SLC7A11, GPX4, FTH1, FPN1 in 16HBE cells, and down-regulated the expressions of ACSL4, TFR1 and NCOA4 in 16HBE cells (P < 0.05). These results suggest that GBFXD can inhibit ferroptosis of airway epithelial cells, reduce airway epithelial damage, alleviate airway inflammation, and prevent and treat the remission period of asthma. Its mechanism of inhibiting ferroptosis may be related to the regulation of iron metabolism-related protein expression and the reduction of Fe2+ accumulation.

     

/

返回文章
返回